• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Humanigen Inc (NQ: HGEN )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Humanigen Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
    From Humanigen, Inc.
    Via Business Wire
    Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
    From Humanigen, Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Tuesday
    Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
    On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
    Via Benzinga
    20 Stocks Moving in Monday's Pre-Market Session
    Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading. Pluristem Therapeutics Inc. (NASDAQ: PSTI) rose 28.5% to $1.89 in pre-... 
    Via Benzinga
    Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
    From Humanigen, Inc.
    Via Business Wire
    Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
    From Humanigen, Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Friday
    Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
    Via Benzinga
    Humanigen to Present at Investor Conferences January 7 and 13, 2022
    From Humanigen, Inc.
    Via Business Wire
    Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
    From Humanigen, Inc.
    Via Business Wire
    Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
    From Humanigen, Inc.
    Via Business Wire
    Stocks Hitting New 52-Week Lows Today
    On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
    Via Benzinga
    Humanigen, Inc. (NASDAQ:HGEN) Investor Notice: Investigation over Possible Wrongdoing
    San Diego, CA -- (SBWIRE) -- 12/13/2021 -- Certain directors of Humanigen, Inc are under investigation over potential breaches of fiduciary duties. 
    Via SBWire
    Exposures COVID-19 Product Safety
    After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News
    Humanigen Inc (NASDAQ: HGEN) announced that The Lancet Respiratory Medicine published results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalized COVID-19... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    65 Biggest Movers From Yesterday
    Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
    Via Benzinga
    27 Stocks Moving in Thursday's Pre-Market Session
    Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)... 
    Via Benzinga
    Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
    From Humanigen, Inc.
    Via Business Wire
    The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
    From Humanigen, Inc.
    Via Business Wire
    These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
    Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
    Via Benzinga
    20 Stocks Moving in Monday's Pre-Market Session
    Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results... 
    Via Benzinga
    Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
    From Humanigen, Inc.
    Via Business Wire
    Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
    From Humanigen, Inc.
    Via Business Wire
    Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
    From Humanigen, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
    Via Benzinga
    Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
    From Humanigen, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Gainers Autolus Therapeutics (NASDAQ:AUTL) stock rose 21.04% to $6.73 during Monday's pre-market session. The company's market cap stands at $490.7 million. As per... 
    Via Benzinga
    Humanigen Announces Release of Abstracts at ASH
    From Humanigen, Inc.
    Via Business Wire
    Humanigen Announces Participation and Presentation at Multiple Conferences in November
    From Humanigen, Inc.
    Via Business Wire
    European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
    From Humanigen, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.